EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The next generation virus‐like particle platform for the treatment of peanut allergy

Jan M Sobczak iD, Pascal S Krenger, Federico Storni iD, Mona O Mohsen, Ina Balke iD, Gunta Reseviča, Matthew D Heath iD, Thalia L Carreno Velazquez, Matthias F Kramer iD, Callum J W Scott, Murray A Skinner, Andris Zeltiņš und 3 weitere

Allergy · 2023

DOI: 10.1111/all.15704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2023. Verfasst von Jan M Sobczak und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University Clinic of Rheumatology and Immunology, Inselspital, Bern, Switzerland. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Anaphylaxis. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation, Allergy Therapeutics, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergy to peanut is one of the leading causes of anaphylactic reactions among food allergic patients. Immunization against peanut allergy with a safe and protective vaccine holds a promise to induce durable protection against anaphylaxis caused by exposure to peanut. A novel vaccine candidate (VLP Peanut), based on virus‐like particles (VLPs), is described here for the treatment of peanut allergy. Methods and Results VLP Peanut consists of two proteins: a capsid subunit derived from Cucumber mosaic virus engineered with a universal T‐cell epitope (CuMV TT ) and a CuMV TT subunit fused with peanut allergen Ara h 2 (CuMV TT ‐Ara h 2), forming mosaic VLPs. Immunizations with VLP Peanut in both naïve and peanut‐sensitized mice resulted in a significant anti‐Ara h 2 IgG response. Local and systemic protection induced by VLP Peanut were established in mouse models for peanut allergy following prophylactic, therapeutic, and passive immunizations. Inhibition of FcγRIIb function resulted in a loss of protection, confirming the crucial role of the receptor in conferring cross protection against peanut allergens other than Ara h 2.

Conclusion

VLP Peanut can be delivered to peanut‐sensitized mice without triggering allergic reactions, while remaining highly immunogenic and offering protection against all peanut allergens. In addition, vaccination ablates allergic symptoms upon allergen challenge. Moreover, the prophylactic immunization setting conferred the protection against subsequent peanut‐induced anaphylaxis, showing the potential for preventive vaccination. This highlights the effectiveness of VLP Peanut as a prospective break‐through immunotherapy vaccine candidate toward peanut allergy. VLP Peanut has now entered clinical development with the study PROTECT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peanut HypersensitivityAnaphylaxisMiceAnimalsProspective StudiesAntigens, PlantAllergensArachis

Stichwörter der Autor:innen

novel therapypeanut allergyvaccinevirus-like particles

Substanzen

Antigens, PlantAllergens

Autor:innen und Institutionen

  • Department of Immunology, University Clinic of Rheumatology and Immunology, Inselspital, Bern, Switzerland.
  • Department of BioMedical Research, University of Bern, Bern, Switzerland.
  • Department of Visceral Surgery and Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
  • Latvian Biomedical Research and Study Centre, Riga, Latvia.
  • Allergy Therapeutics (UK) Ltd., Worthing, UK.
  • Bencard Allergie GmbH, Munich, Germany.

ORCID-Profile: Jan M Sobczak, Federico Storni, Ina Balke, Matthew D Heath, Matthias F Kramer, Monique Vogel, Martin F Bachmann

Förderung

  • Swiss National Science Foundation
  • Allergy Therapeutics
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Sobczak, J. M., Krenger, P. S., Storni, F., Mohsen, M. O., Balke, I., Reseviča, G., Heath, M. D., Carreno Velazquez, T. L., Kramer, M. F., Scott, C. J. W., Skinner, M. A., Zeltiņš, A., Kündig, T. M., Vogel, M., & Bachmann, M. F. (2023). The next generation virus‐like particle platform for the treatment of peanut allergy. Allergy. https://doi.org/10.1111/all.15704

Vancouver

Sobczak JM, Krenger PS, Storni F, Mohsen MO, Balke I, Reseviča G, et al. The next generation virus‐like particle platform for the treatment of peanut allergy. Allergy. 2023. doi:10.1111/all.15704

BibTeX
@article{Sobczak2023,
  author = {Sobczak, Jan M and Krenger, Pascal S and Storni, Federico and Mohsen, Mona O and Balke, Ina and Reseviča, Gunta and Heath, Matthew D and Carreno Velazquez, Thalia L and Kramer, Matthias F and Scott, Callum J W and Skinner, Murray A and Zeltiņš, Andris and Kündig, Thomas M and Vogel, Monique and Bachmann, Martin F},
  title = {The next generation virus‐like particle platform for the treatment of peanut allergy},
  journal = {Allergy},
  year = {2023},
  doi = {10.1111/all.15704}
}
Kostenlos starten →